Cancer Survivorship and Subclinical Myocardial Damage: The Atherosclerosis Risk in Communities (ARIC) Study.
Cancer survivors may have an excess risk of cardiovascular disease (CVD) resulting from toxicities of cancer therapies and high burden of CVD risk factors. We sought to evaluate the association of cancer survivorship with subclinical myocardial damage, as assessed by elevated high-sensitivity cardiac Troponin T (hs-cTnT). We included 3,512 participants of the ARIC Study who attended Visit 5 (2011-2013) and were free of CVD (coronary heart disease, heart failure, or stroke). We used multivariable logistic regression to evaluate the cross-sectional associations of survivorship from any, non-sex-related, and sex-related cancers (e.g., breast, prostate) with elevated hs-cTnT (≥14 ng/L). Of 3,512 participants (mean age 76; 62% women; 21% black), 19% were cancer survivors. Cancer survivors had significantly higher odds of elevated hs-cTnT (OR 1.26, 95% CI 1.03, 1.53). Results were similar for survivors of non-sex-related and colorectal cancers. There was no association between survivorship from breast and prostate cancers and elevated hs-cTnT. Results were similar after additional adjustments for CVD risk factors. Survivors of some cancers may be more likely to have elevated hs-cTnT than persons without prior cancer. The excess burden of subclinical myocardial damage in this population may not be fully explained by traditional CVD risk factors.